Publications by authors named "Rachel Dunsdon"

Claim this Profile
I
Identification of a series of 1,3,4-oxadiazol-2-amines as potent alpha-7 agonists with efficacy in the novel object recognition model of cognition.
John Skidmore, Zeenat Atcha, Emmanuelle Boucherat, Laura Castelletti, Deborah W Chen, Rachel M Dunsdon

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of 2-fluoro-N-(3-fluoro-4-(5-((4-morpholinobutyl)amino)-1,3,4-oxadiazol-2-yl)phenyl)benzamide, a full agonist of the alpha-7 nicotinic acetylcholine receptor showing efficacy in the novel object recognition model of cognition enhancement.
John Skidmore, Zeenat Atcha, Emmanuelle Boucherat, Laura Castelletti, Deborah W Chen, Rachel M Dunsdon

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.
Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

Bioorg Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics.
Nicolas Charrier, Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
Nicolas Charrier, Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation of BACE-1 inhibitors part 2: Optimisation of the non-prime side substituent.
Nicolas Charrier, Brian Clarke, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation of hydroxyethylamine BACE-1 inhibitors: optimizing potency and oral bioavailability.
Nicolas Charrier, Brian Clarke, Leanne Cutler, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

J Med Chem· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.
Brian Clarke, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon, Andrew Faller

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).
Brian Clarke, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon, Andrew Faller

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells.
Paul Beswick, Nicolas Charrier, Brian Clarke, Emmanuel Demont, Colin Dingwall, Rachel Dunsdon

Bioorg Med Chem Lett· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity.
Kevin R Guertin, Lina Setti, Lida Qi, Rachel M Dunsdon, Brian W Dymock

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis